Back to search

Article

COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial.

2021-09-16

Abstract excerpt

<h4>Background: </h4> The current COVID-19 pandemic has had a major influence on our daily lives. The most frequent early symptoms associated with SARS-CoV-2 infection are coughing, fever, rhinitis, and loss of smell and taste. If the infection progresses to the lower respiratory tract, it can cause massive inflammation of the pulmonary system, which can be life threatening. There is urgent need for a broadly avai...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3078d349-f84b-5c3e-bb3b-0662aeb3296b
DOI
10.21203/rs.3.rs-864566/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial.DOI 10.21203/rs.3.rs-864566/v1
COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN) Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients – results from a randomized, double-blind, placebo-controlled phase II clinical trial.Semantic proximity
A randomized, placebo-controlled trial of a nasal spray solution containing broadly potent neutralizing antibodies against SARS-CoV-2 variants in healthy volunteersSemantic proximity
The Real-World Effectiveness of an Intranasal Spray A8G6 Antibody Cocktail in the Post-Exposure Prophylaxis of COVID-19Semantic proximity
The real-world effectiveness of an intranasal spray A8G6 antibody cocktail in the post-exposure prophylaxis of COVID-19Semantic proximity
Hydroxychloroquine with or Without Azithromycin for Treatment of Early SARS-CoV-2 Infection Among High-Risk Outpatient Adults: A Randomized Clinical TrialSemantic proximity
Therapeutic application of alpha-1-antitrypsin in COVID-19Semantic proximity
Safety, tolerability and viral kinetics during SARS-CoV-2 human challengeSemantic proximity
A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis – ICE COVIDSemantic proximity
The efficacy and safety of an intranasal spray COVID-19 vaccine in a randomized double-blind placebo-controlled phase Ⅲ trial during Omicron periodSemantic proximity
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Semantic proximity
TaffiX® nasal powder spray forms an effective barrier against infectious new variants of SARS-CoV-2 (Alpha, Beta and Delta)Semantic proximity
Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).Semantic proximity
Select a neighboring publication to make it the new centre.